Size: | Price | Quantity | |
---|---|---|---|
5 mg | $42.00 | ||
25 mg | $180.00 |
DY131 (95167-41-2) is a selective agonist at estrogen-related receptors ERRβ and ERRγ with minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.1 Displays antiproliferative activity in prostate cancer cells.2 Promotes hormone production and cell fusion in cytotrophoblasts.3 In breast cancer cells DY131 arrests cells in G2/M and causes mitotic spindle defects.4 Inhibits osteoclastogenesis and protects against inflammatory bone loss induced by LPS in vivo.5
References/Citations:
1) Yu and Forman (2005), Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma; Bioorg. Med. Chem. Lett., 15 1311
2) Yu et al. (2008), Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21 (WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer; Oncogene, 27 3313
3) Poidatz et al. (2015), Trophoblast syncytialisation necessitates mitochondrial function through estrogen-related receptor-τ; Mol. Hum. Reprod., 21 206
4) Heckler et al. (2016), Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRß2) splice variant in breast cancer; Oncotarget, 7 47201
5) Kim et al. (2019), Estrogen-related receptor τ negatively regulates osteoclastogenesis and protects against inflammatory bone loss; J. Cell Physiol., 234 1659
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
DY131 (95167-41-2) is a selective agonist at estrogen-related receptors ERRβ and ERRγ with minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.1 Displays antiproliferative activity in prostate cancer cells.2 Promotes hormone production and cell fusion in cytotrophoblasts.3 In breast cancer cells DY131 arrests cells in G2/M and causes mitotic spindle defects.4 Inhibits osteoclastogenesis and protects against inflammatory bone loss induced by LPS in vivo.5
References/Citations:
1) Yu and Forman (2005), Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma; Bioorg. Med. Chem. Lett., 15 1311
2) Yu et al. (2008), Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21 (WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer; Oncogene, 27 3313
3) Poidatz et al. (2015), Trophoblast syncytialisation necessitates mitochondrial function through estrogen-related receptor-τ; Mol. Hum. Reprod., 21 206
4) Heckler et al. (2016), Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRß2) splice variant in breast cancer; Oncotarget, 7 47201
5) Kim et al. (2019), Estrogen-related receptor τ negatively regulates osteoclastogenesis and protects against inflammatory bone loss; J. Cell Physiol., 234 1659
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.